Atai Beckley N.V. (ATAI) Stock Forecast & Price Target

Compare

2,050 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ATAI Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Atai

Beckley N.V.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ATAI Stock 12 Month Forecast

Average Price Target

$14.33

▲(292.69% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Atai Beckley N.V. in the last 3 months. The average price target is $14.33 with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 292.69% change from the last price of $3.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.333333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,5.32,6.960000000000001,8.6,10.24,11.88,13.52,15.16,16.8,18.44,20.080000000000002,21.720000000000002,23.36,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.49948717948718,5.318974358974359,6.138461538461539,6.957948717948718,7.777435897435899,8.596923076923078,9.416410256410257,10.235897435897437,11.055384615384616,11.874871794871796,12.694358974358975,13.513846153846155,{"y":14.333333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.68,4.166153846153846,4.6523076923076925,5.138461538461539,5.624615384615385,6.110769230769231,6.596923076923077,7.0830769230769235,7.569230769230769,8.055384615384616,8.541538461538462,9.027692307692307,9.513846153846155,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.09,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$14.33

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$25

Buy

584.93%

Upside

Reiterated

03/17/26

Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price

Ami Fadia

Needham

$14

Buy

283.56%

Upside

Reiterated

03/09/26

ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection

Andrew Tsai

Jefferies

$10

Buy

173.97%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay Olson

Oppenheimer

$16

Buy

338.36%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Justin Walsh

JonesTrading

$16

Buy

338.36%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Corbus Pharmaceuticals (NASDAQ: CRBP) and Atai Beckley N.V. (NASDAQ: ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

03/08/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)

Sumant Kulkarni

Canaccord Genuity

$14

Buy

283.56%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Atai Beckley N.V. (NASDAQ: ATAI) and Artivion (NYSE: AORT)

Harry Gillis

Berenberg Bank

$13

Buy

256.16%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and Atai Beckley N.V. (NASDAQ: ATAI)

Michael Okunewitch

Maxim Group

$10

Buy

173.97%

Upside

Reiterated

02/27/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI)

Eddie Hickman

Guggenheim

$11

Buy

201.37%

Upside

Initiated

01/20/26

Atai Beckley initiated with a Buy at GuggenheimAtai Beckley initiated with a Buy at Guggenheim

Nathan Weinstein

Aegis Capital

Buy

119.18%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Elemer Piros

Lucid Capital

$12

Buy

228.77%

Upside

Initiated

06/06/25

Atai Life Sciences initiated with a Buy at Lucid CapitalAtai Life Sciences initiated with a Buy at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$25

Buy

584.93%

Upside

Reiterated

03/17/26

Buy Rating on BPL-003 Underpinned by Strong Phase 2a Efficacy, De-Risked Phase 3 Program, and Upside to $25 Target Price

Ami Fadia

Needham

$14

Buy

283.56%

Upside

Reiterated

03/09/26

ATAI Life Sciences: Reiterating Buy on BPL-003’s Differentiated TRD Profile, Pricing Power, and Long-Dated IP Protection

Andrew Tsai

Jefferies

$10

Buy

173.97%

Upside

Reiterated

03/09/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay Olson

Oppenheimer

$16

Buy

338.36%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atai Beckley N.V. (NASDAQ: ATAI), BridgeBio Oncology Therapeutics (NASDAQ: BBOT) and Biohaven Ltd. (NYSE: BHVN)

Justin Walsh

JonesTrading

$16

Buy

338.36%

Upside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Editas Medicine (NASDAQ: EDIT), Corbus Pharmaceuticals (NASDAQ: CRBP) and Atai Beckley N.V. (NASDAQ: ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

03/08/26

Analysts Conflicted on These Healthcare Names: Biohaven Ltd. (NYSE: BHVN) and Atai Beckley N.V. (NASDAQ: ATAI)

Sumant Kulkarni

Canaccord Genuity

$14

Buy

283.56%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Atai Beckley N.V. (NASDAQ: ATAI) and Artivion (NYSE: AORT)

Harry Gillis

Berenberg Bank

$13

Buy

256.16%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Alcon (NYSE: ALC) and Atai Beckley N.V. (NASDAQ: ATAI)

Michael Okunewitch

Maxim Group

$10

Buy

173.97%

Upside

Reiterated

02/27/26

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Atai Beckley N.V. (ATAI)

Eddie Hickman

Guggenheim

$11

Buy

201.37%

Upside

Initiated

01/20/26

Atai Beckley initiated with a Buy at GuggenheimAtai Beckley initiated with a Buy at Guggenheim

Nathan Weinstein

Aegis Capital

Buy

119.18%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Elemer Piros

Lucid Capital

$12

Buy

228.77%

Upside

Initiated

06/06/25

Atai Life Sciences initiated with a Buy at Lucid CapitalAtai Life Sciences initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atai Beckley N.V.

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+28.10%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +28.10% per trade.

1 Year

Ritu BaralTD Cowen

Success Rate

9/15 ratings generated profit

Average Return

+57.11%

Copying Ritu Baral's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +57.11% per trade.

2 Years

xxx

Success Rate

12/15 ratings generated profit

Average Return

+106.07%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +106.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATAI Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ATAI has received 21 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ATAI average Analyst price target in the past 3 months is 14.33.

Each month's total comprises the sum of three months' worth of ratings.

ATAI Financial Forecast

ATAI Earnings Forecast

Next quarter’s earnings estimate for ATAI is -$0.11 with a range of -$0.16 to -$0.07. The previous quarter’s EPS was -$0.28. ATAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Sales Forecast

Next quarter’s sales forecast for ATAI is $338.00K with a range of $0.00 to $1.50M. The previous quarter’s sales results were $749.00K. ATAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Stock Forecast FAQ

What is ATAI’s average 12-month price target, according to analysts?

Based on analyst ratings, Atai Beckley N.V.’s 12-month average price target is 14.33.

What is ATAI’s upside potential, based on the analysts’ average price target?

Atai Beckley N.V. has 292.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ATAI a Buy, Sell or Hold?

Atai Beckley N.V. has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Atai Beckley N.V.’s price target?

The average price target for Atai Beckley N.V. is 14.33. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $10.00. The average price target represents 292.69% Increase from the current price of $3.65.

What do analysts say about Atai Beckley N.V.?

Atai Beckley N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of ATAI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Atai Beckley N.V. (ATAI) Stock Forecast & Price Target

ATAI Analyst Ratings

ATAI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Atai Beckley N.V.

ATAI Analyst Recommendation Trends

ATAI Financial Forecast

ATAI Earnings Forecast

ATAI Sales Forecast

ATAI Stock Forecast FAQ

Detailed List of Analyst Forecasts